<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tromethamine (THAM): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tromethamine (THAM): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tromethamine (THAM): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11897" href="/d/html/11897.html" rel="external">see "Tromethamine (THAM): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12868" href="/d/html/12868.html" rel="external">see "Tromethamine (THAM): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54460004"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tham</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F232051"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alkalinizing Agent, Parenteral</li></ul></div>
<div class="block doa drugH1Div" id="F232039"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>: Limit dose to amount sufficient to increase blood pH to near normal limits (~7.35) and to correct metabolic acidosis. Retention of tromethamine in patients with impaired kidney function may occur and may lead to metabolic alkalosis. Evaluate blood pH and clinical status during therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d50e75d5-2476-4c4f-b982-2ea7c4113c66">Correction of acidity of acid citrate dextrose blood used in cardiac bypass surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Correction of acidity of acid citrate dextrose blood used in cardiac bypass surgery:</b> 15 to 77 mL of 0.3 M solution (500 mg to 2.5 g) added to each 500 mL of acid citrate dextrose (ACD) blood; 62 mL (2g) added to 500 mL of ACD blood is adequate for most adults.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89fdda0f-fd67-421b-814d-421a8dcaf5fd">Estimated dose when buffer base deficit is known</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Estimated dose when buffer base deficit is known: IV:</b> tromethamine dose (mL of 0.3 M solution) = body weight (kg) x base deficit (mEq/L) x 1.1.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9cc93230-d560-4961-8d3f-1b380e3527de">Metabolic acidosis associated with cardiac arrest</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis associated with cardiac arrest:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 111 to 333 mL of 0.3 M solution (3.6 to 10.8 g); additional amounts may be required to control acidosis after arrest reversed.</p>
<p style="text-indent:-2em;margin-left:4em;">Open chest: Intraventricular cavity: 62 to 185 mL of 0.3 M solution (2 to 6 g). <b>Note:</b> Do not inject into cardiac muscle.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea0f9c02-236f-441a-a81c-226ba9d1dba2">Metabolic acidosis associated with cardiac bypass surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis associated with cardiac bypass surgery: IV: </b>500 mL of 0.3 M solution (150 mEq) is adequate for most adults; in severe cases up to 1,000 mL may be needed; average dose: 9 mL/kg (324 mg/kg) of 0.3 M solution; maximum single dose: 500 mg/kg over at least 1 hour; reevaluate blood pH and clinical status to guide repeat dosing.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990872"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Tromethamine is substantially excreted by the kidneys; use with caution; monitor ECG and potassium levels.</p></div>
<div class="block doha drugH1Div" id="F50988161"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F232040"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812560"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12868" href="/d/html/12868.html" rel="external">see "Tromethamine (THAM): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose dependent upon severity and progression of acidosis; doses should be administered slowly to prevent overtreatment. Tromethamine is available as a 0.3 M solution (THAM). Each mL of THAM = 0.3 mmol = 36 mg = 0.3 mEq</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d73b4940-94c8-457d-b8da-b428566ee843">Metabolic acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis:</b> Infants, Children, and Adolescents: IV: Empiric dosage calculation equation based upon base deficit:</p>
<p style="text-indent:-2em;margin-left:4em;">Dose (mL) of THAM = body weight (kg) x base deficit (mEq/L) x 1.1*</p>
<p style="text-indent:-2em;margin-left:4em;">*Factor of 1.1 accounts for an approximate reduction of 10% in buffering capacity due to the presence of sufficient acetic acid to lower the pH of the 0.3 M solution to approximately 8.6.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="230392e8-2901-4654-9da9-a29e5297683a">Metabolic acidosis with respiratory distress</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis with respiratory distress:</b> Infants: IV: Initial: 1 mL/kg for each pH unit below 7.4; additional doses to be determined by changes in PaO<sub>2</sub>, pH, and pCO<sub>2</sub>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a125bd1-364f-4b9c-833f-890267a4e4bc">Metabolic acidosis with cardiac arrest</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis with cardiac arrest:</b> Limited data available: <b>Note:</b> Routine use of buffering agents during cardiac arrest not recommended (AHA [Kleinman 2010]):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: THAM: IV: 1 mL/kg should raise bicarbonate concentration by 1 mEq/L (Fuhrman 2016).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729860"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Tromethamine is substantially excreted by the kidneys; use with caution; monitor ECG and potassium serum levels.</p></div>
<div class="block dohp drugH1Div" id="F52729861"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F232021"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Localized phlebitis, venospasm, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia, hypervolemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis (resulted during delivery via umbilical venous catheter)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site infection, local irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F232033"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Uremia or anuria; chronic respiratory acidosis (neonates); salicylate intoxication (neonates).</p></div>
<div class="block war drugH1Div" id="F232018"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. May cause tissue inflammation, sloughing, and necrosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: May cause hypoglycemia with rapid administration or extremely large doses; monitor serum blood glucose during and after therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: Large doses may decrease respiratory ventilation due to increased blood pH and reduced CO<sub>2</sub>; adjust dose so that blood pH is not increased above normal. Monitor closely especially if patient not intubated. In patients with concomitant respiratory acidosis, use only with mechanical ventilation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; possibly decrease excretion of tromethamine; use ECG monitoring and monitor serum potassium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: Drug should not be given for a period of &gt;24 hours, unless for a life-threatening situation.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878661"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Avoid infusion via low-lying umbilical venous catheters (particularly with concentrations ≥1.2 M) due to associated risk of hepatocellular necrosis; severe local tissue necrosis and sloughing may occur if solution extravasates; administer via central line or large peripheral vein slowly. Due to the greater osmotic effects of tromethamine, use of sodium bicarbonate for the treatment of acidotic neonates and infants with respiratory distress syndrome may be preferred; may cause prolonged hypoglycemia in premature and full-term neonates or with rapid IV infusion and overdosage. Monitor pH carefully as large doses may increase blood pH greater than normal which may result in depressed respiration.</p></div>
<div class="block foc drugH1Div" id="F54460005"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tham: 30 mEq/100 mL (500 mL) [latex free]</p></div>
<div class="block geq drugH1Div" id="F232014"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324044"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tham Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mEq/100 mL (per mL): $0.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F232030"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Correction of metabolic acidosis in cardiac bypass surgery: Administer by slow IV infusion over at least 1 hour (maximum rate: 500 mg/kg over at least 1 hour); rapid administration may result in prolonged hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">Correction of acid citrate dextrose (ACD) blood acidity in cardiac bypass surgery: Add to each 500 mL of ACD blood used to prime the pump-oxygenator.</p>
<p style="text-indent:-2em;margin-left:2em;">Correction of metabolic acidosis in cardiac arrest: If chest is open, instill directly into ventricular cavity; do <b>NOT</b> inject into cardiac muscle. If chest is not open, inject into a large peripheral vein. Administer at same time as other standard resuscitative measures.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant (with IV administration); ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block admp drugH1Div" id="F52613983"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV infusion: Infuse undiluted solution (0.3 M) slowly; may administer via central line (preferred) or large peripheral vein using a large needle.</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolic acidosis: Administer over at least 1 hour.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant (with IV administration); ensure proper needle or catheter placement prior to and during administration; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block use drugH1Div" id="F232029"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Metabolic acidosis:</b> Correction of metabolic acidosis associated with cardiac bypass surgery or cardiac arrest; to correct acidity of stored blood that is preserved with acid citrate dextrose; metabolic acidosis associated with respiratory distress syndrome in neonates and infants.</p></div>
<div class="block mst drugH1Div" id="F3123324"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tromethamine may be confused with TrophAmine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300183"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223545"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.  Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Alkalinizing Agents may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Alkalinizing Agents may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F3341462"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F17969758"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tromethamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering tromethamine to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F232025"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes (especially potassium, blood glucose); renal function, urinary output, arterial blood gases, ECG monitoring, fluid status, ventilation rate.</p>
<p style="text-indent:-2em;margin-left:2em;">Check infusion site frequently during administration.</p></div>
<div class="block rer drugH1Div" id="F232028"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Blood pH (physiologic): 7.38-7.42</p></div>
<div class="block pha drugH1Div" id="F232017"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline"> Acts as a proton acceptor, which combines with hydrogen ions, liberating  bicarbonate buffer, to correct acidosis. It buffers both metabolic and respiratory acids, limiting carbon dioxide generation. Also an osmotic diuretic.</p></div>
<div class="block phk drugH1Div" id="F232032"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 30% of dose is not ionized.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;75%) within 8 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992801"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tris fresenius kabi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">3 M Trometamol | Tham Koehler</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aci-tham</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tham Koehler</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Addex-tham</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Trometamina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9414329">
<a name="9414329"></a>Adrogue HJ and Madias NE, “Management of Life-Threatening Acid-Base Disorders: First of Two Parts,” <i>N Engl J Med</i>, 1998, 338(1):26-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tromethamine-tham-drug-information/abstract-text/9414329/pubmed" id="9414329" target="_blank">9414329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al, “Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,” <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tromethamine-tham-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4951641">
<a name="4951641"></a>Gupta JM, Dahlenburg GW, Davis JA. Changes in blood gas tensions following administration of amine buffer THAM to infants with respiratory distress syndrome. <i>Arch Dis Child</i>. 1967;42(224):416-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tromethamine-tham-drug-information/abstract-text/4951641/pubmed" id="4951641" target="_blank">4951641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tromethamine-tham-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>
</li>
<li>
<div class="reference">
                  Nahas GG, Sutin KM, Fermon C, et al, “Guidelines for the Treatment of Acidaemia With THAM,” <i>Drugs</i>, 1998, 55(2): 191-224.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4868611">
<a name="4868611"></a>Strauss J. Tris (hydroxymethyl) amino-methane (Tham): a pediatric evaluation.<i> Pediatrics</i>. 1968;41(3):667-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tromethamine-tham-drug-information/abstract-text/4868611/pubmed" id="4868611" target="_blank">4868611</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tham (tromethamine) [prescribing information]. Lake Forest, IL: Hospira Inc; February 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10027 Version 139.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
